(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
Live Chart Being Loaded With Signals
Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom...
Stats | |
---|---|
本日の出来高 | 254 775 |
平均出来高 | 546 210 |
時価総額 | 17.53M |
EPS | £0 ( 2024-04-10 ) |
Last Dividend | £0 ( N/A ) |
Next Dividend | £0 ( N/A ) |
P/E | -3.07 |
ATR14 | £0.232 (1.26%) |
Destiny Pharma PLC 相関
10 最も正の相関 | |
---|---|
WINE.L | 0.9 |
GHT.L | 0.889 |
INDV.L | 0.883 |
DPEU.L | 0.873 |
ONC.L | 0.859 |
MCM.L | 0.853 |
RMMC.L | 0.842 |
UPGS.L | 0.834 |
RWS.L | 0.833 |
DGN.L | 0.829 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Destiny Pharma PLC 財務諸表
Annual | 2023 |
収益: | £831 552 |
総利益: | £831 552 (100.00 %) |
EPS: | £-0.0624 |
FY | 2023 |
収益: | £831 552 |
総利益: | £831 552 (100.00 %) |
EPS: | £-0.0624 |
FY | 2022 |
収益: | £154 499 |
総利益: | £142 171 (92.02 %) |
EPS: | £-0.0926 |
FY | 2021 |
収益: | £0.00 |
総利益: | £0.00 (0.00 %) |
EPS: | £-0.0890 |
Financial Reports:
No articles found.
Destiny Pharma PLC
Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase III clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in Phase I clinical trial for the treatment of skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product, which is in preclinical stage for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Biofilm that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. In addition, the company is involved in the development of XF drugs for the treatment of respiratory, oral mucosa, and ocular infection diseases. Destiny Pharma plc has collaboration agreements with China Medical System Holdings Limited; SporeGen Limited; the University of Southampton; Aston University; the University of Sheffield; and Cardiff University and Tianjin Medical University. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。